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Abstract
Background: Well differentiated papillary mesothelioma of the peritoneum (WDPMP) is a rare variant of epithelial
mesothelioma of low malignancy potential, usually found in women with no history of asbestos exposure. In this
study, we perform the first exome sequencing of WDPMP.
Results: WDPMP exome sequencing reveals the first somatic mutation of E2F1, R166H, to be identified in human
cancer. The location is in the evolutionarily conserved DNA binding domain and computationally predicted to be
mutated in the critical contact point between E2F1 and its DNA target. We show that the R166H mutation
abrogates E2F1’s DNA binding ability and is associated with reduced activation of E2F1 downstream target genes.
Mutant E2F1 proteins are also observed in higher quantities when compared with wild-type E2F1 protein levels
and the mutant protein’s resistance to degradation was found to be the cause of its accumulation within mutant
over-expressing cells. Cells over-expressing wild-type E2F1 show decreased proliferation compared to mutant over-
expressing cells, but cell proliferation rates of mutant over-expressing cells were comparable to cells over-
expressing the empty vector.
Conclusions: The R166H mutation in E2F1 is shown to have a deleterious effect on its DNA binding ability as well
as increasing its stability and subsequent accumulation in R166H mutant cells. Based on the results, two
compatible theories can be formed: R166H mutation appears to allow for protein over-expression while minimizing
the apoptotic consequence and the R166H mutation may behave similarly to SV40 large T antigen, inhibiting
tumor suppressive functions of retinoblastoma protein 1.
Background
Mesothelioma is an uncommon neoplasm that develops
from the mesothelium, the protective lining covering a
majority of the body’s internal organs, and is divided
into four subtypes: pleural, peritoneum, pericardium and
tunica vaginalis [1]. While malignant peritoneal
mesothelioma (MPM) is an aggressive tumor mainly
afflicting asbestos-exposed males in the age range of 50
to 60 years old [2], well-differentiated papillary mesothe-
lioma of the peritoneum (WDPMP), a rare subtype of
epithelioid mesothelioma [1] with fewer than 60 cases
described in the literature [3], is generally considered to
be a tumor of low malignant potential found predomi-
nately in young women with no definitive exposure to
asbestos [3]. While much scientific research has been
done on asbestos-related malignant mesothelioma [4-7],
the rarity of WDPMP coupled with its good prognosis
relegated its research to case reports and reviews by
medical oncologists concentrating in the area of diagno-
sis, prognosis and treatment options.
Second generation sequencing technologies coupled
with newly developed whole exome capturing technolo-
gies [8] allow for rapid, relatively inexpensive
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omes by concentrating on the critical coding areas of
the genome. Here, we report the first exome sequencing
of a WDPMP tumor, its tumor-derived cell line and a
matched control sample employing Agilent SureSelect
All Exon capturing technology to selectively capture all
human exons followed by Illumina massively parallel
genomic sequencing. We developed methodology and
informatics to obtain a compact graphical view of the
exome as well as detailed analysis of single nucleotide
variants (SNVs). We demonstrate that while this
WDPMP tumor does not exhibit any of the chromoso-
mal aberrations and focal deletions commonly asso-
ciated with asbestos-related mesothelioma [5], it does
exhibit the first reported somatic single nucleotide
mutation of E2F1 (E2F transcription factor 1) in cancer,
with the mutation affecting one of two evolutionarily
conserved arginine residues responsible for motif recog-
nition and DNA binding.
Results
WDPMP exome sequencing: mutation landscape changes
big and small
Exon captured sample libraries comprising DNA from a
WDPMP tumor, DNA from the patient’sb l o o d ,a n d
DNA from a tumor-derived cell line were sequenced
using Illumina GAIIx 76-bp paired-end sequencing tech-
nology; Table 1 provides a summary of the sequenced
exome data for the WDPMP tumor and its matched
control sample as well as the tumor-derived cell line; in
total, approximately 34 Gbases of sequence data were
obtained in which > 92% of the reads successfully
mapped back to the hg18 reference genome using the
BWA short read aligner [9]. After removal of low quality
reads and PCR duplicate reads using SAMtools [10],
approximately 24.3 Gbases of sequence data remained.
Of the remaining sequence data, approximately 64%
(approximately 15.5 Gbases) fell within the exon regions,
with the average exome coverage per sample being 152×
depth. Figure 1 shows the breakdown of coverage versus
sequencing depth; key statistics include that 97% of the
e x o m ew a sc o v e r e db ya tl e a s tas i n g l eg o o dq u a l i t y
read, approximately 92% of the exome was covered by
at least ten good quality reads, and 82 to 86% of the
exome was covered by at least 20 reads, indicating that
the overall exome capturing and sequencing were suc-
cessful, generating large amounts of good quality data.
A novel way to visualize large copy number changes
using exome sequencing data is the use of HilbertVis
[11], an R statistical package, to plot exome sequencing
depth versus chromosomal position in a compact gra-
phical manner. Copy number changes, if present, will
reveal themselves through color intensity changes in
regions of the plot where copy number change occurs
when comparing between tumor/cell line versus normal
samples. Figure 2 shows the Hilbert plots of the
sequenced tumor, tumor-derived cell line and normal
blood sample exomes, revealing some systemic capturing
biases but no deletion/amplification events, with particu-
lar attention paid to known somatic deletions of 3p21,
9p13~21 and 22q associated with loss of RASSF1A (RAS
association family 1A), CDKN2A (cyclin-dependent
kinase inhibitor 2A) and NF2 (neurofibromin 2) genes,
respectively, in malignant mesothelioma [12]. Sequen-
cing depth was also adequate for the regions of exon
capture for these genes (Additional file 1), indicating
these genes were truly not somatically mutated and that
any lack of detected mutations was not due to a lack of
coverage.
Since the Hilbert plots showed no gross anomalies, we
turned our attention to mining the exome data for
somatic single nucleotide mutations. The SNV discovery
pipeline, described in the Materials and methods sec-
tion, was performed using the Genome Analyzer Toolkit
[13] for the tumor, normal and cell line exomes. Filter-
ing was set to accept candidate SNVs with a quality/
depth score > 3 and were present in both the tumor
and cell line but not in the normal sample. Nineteen
potential somatic mutations remain and these were vali-
dated using Sanger sequencing (Additional file 2); E2F1,
PPFIBP2 (liprin beta 2) and TRAF7 (TNF receptor-asso-
ciated factor 7) were validated to contain true somatic
mutations (Additional file 3).
The E2F1 R166H mutation affects a critical DNA binding
residue
The E2F1 R166H somatic mutation is of particular
interest as there is no reported mutation of the E2F1
gene in cancer. Figure 3 (top) shows the genomic
Table 1 Summary of overall WDPMP exome sequencing
Sample ID
Tumor Cell line Normal
Raw reads 187,023,594 119,030,552 190,772,020
Unalignable reads 14,717,058 3,778,934 14,190,612
Aligned reads 172,306,536 115,251,618 176,581,408
Percentage alignable 92.13% 96.83% 92.56%
Reads passing filter 129,919,859 92,512,679 137,134,828
Percentage remaining after filter 69.47% 77.72% 71.88%
Number of PCR duplicates 8,498,978 15,903,654 6,070,718
Percentage PCR duplicates 6.54% 17.19% 4.43%
Reads within exome 80,042,870 49,312,008 80,869,734
Percentage reads overall in
exome
61.61% 53.30% 58.97%
Percentage exome covered at
1×
97.10% 96.80% 97.00%
Percentage exome covered at
20×
86.80% 82.40% 86.30%
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Page 2 of 14location of E2F1 as well as the specific location of the
mutation. Sanger sequencing around the mutated
nucleotide of the tumor, cell line and normal sample
revealed the mutation to be heterozygous (Additional
file 3). A check of UniProt for E2F1 [UniProtKB:
Q01094] showed the mutation to be located in the
DNA binding domain of the protein. To study the evo-
lutionary conservation of the R166 residue, a CLUS-
TALW [14] analysis was performed on paralogues of
the human E2F family and SNP analysis, using SNPs3D
[15], was performed across orthologues of E2F1. Figure
3 (bottom) shows the results of the paralogue and
orthologue conservation analyses; the conclusion drawn
is that the R166 residue is conserved in evolution and
has never been observed to be mutated.
Since there is no E2F1 crystal structure containing
the R166 residue, the X-ray crystal structure of E2F4-
DP [PDB:1CF7] was used to determine the location of
the mutation and its role in DNA binding using the
Swiss-PDB viewer [16]. The E2F4 DNA binding struc-
ture was used as an adequate representation of its
E2F1 counterpart due to the conserved status of the
R165-R166 residues across the E2F paralogues (Figure
3, bottom right) as well as the affected residue being a
part of the winged-helix DNA-binding motif observed
across the whole E2F family of transcription factors
[17]. The arginine residues of E2F4 and its dimeriza-
tion partner DP are responsible for DNA binding (Fig-
ure 4, top) and the analysis clearly shows R166 as one
of four arginine residues contacting the DNA target
(Figure 4, bottom).
Since the crystal structure for the DNA binding
domain of E2F4 was available, computational modeling
of the mutation was amenable to homology modeling
using SWISS-MODEL [18]. Figure 5 (top) shows the
modeling of the E2F1 mutant and wild-type DNA bind-
ing domain; Calculation of individual residue energy
using ANOLEA (Atomic Non-Local Environment
Assessment) [19] and GROMOS (Groningen Molecular
Simulation) [20] indicated that the mutant histidine’s
predicted position and conformation were still favorable
as indicated by the negative energy value (Figure 5, bot-
tom). While there is a difference in the size and charge
between the mutant histidine and wild-type arginine
residue coupled with a conformational shift at the
mutated position, the overall three-dimensional struc-
ture of the domain appears minimally affected by the
mutation. Even though the effect of the mutation on
DNA binding is computationally inconclusive, these
results did pinpoint the structural location and func-
tional importance of the R166 residue, thus pointing the
way for the functional experiments reported below.
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Figure 1 Cumulative WDPMP exome coverage for the tumor, normal sample and tumor derived cell line. Cumulative exome coverage
curve for the tumor (blue), normal sample (orange) and cell line (yellow) is generated by plotting the percentage of the exome represented by
different read depths where read depth is defined as the number of individual 75-bp sequenced reads mapped to a particular exome position.
The ‘fat tail’ of the graph indicates a bias in the capturing technology as small sections of the exome are over-represented.
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Figure 2 Compact representation of the WDPMP exome using Hilbert plots. Instead of linearly plotting the sequencing depth versus the
exome DNA string, HilbertVis [11] computationally wraps the DNA string in a fractal manner onto a two-dimensional grid of pre-determined size
and represents the coverage depth via a heat map similar to gene expression data. Red and blue color heat mapping is used to demarcate the
borders of each chromosome.
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Paralogues
E2F6  ...KLGVR - KRRVYDITN...
E2F5  ...TLAVRQK RRIYDITN...
E2F4  ...TLAVRQK RRIYDITN...
E2F3  ...VLKVQ - KRRIYDITN...
E2F2  ...VLDVQ - KRRIYDITN...
E2F1 ...VLKVQ - KHRIYDITN ...
Orthologues
man         ...VLKVQK RRIYDITN...
mutated     ... VLKVQK HRIYDITN...
Rhesus      ...VLDVQK RRIYDITN...
chimp       ...KLAVHR RRIYDIIS...
equine      ...VLDVQK RRIYDITN...
mouse       ...VLDVQK RRIYDITN...
chicken     ...VLKVQK RRIYDITN...
platypus    ...TLRVRK RRVYDITN...
zebrafish ...KLGARK RRVYDITS...
E2F1
Figure 3 Location and conservation analysis of E2F1 R166H. E2F1 genomic location, exon location of c.493 c > Y mutation and results of
E2F1 mutation validation and conservation analysis. Top: the chromosomal location of E2F1 and the location of its exons. The exon numbering
indicates E2F1 is located on the reverse strand and the c.493C > Y mutation is location on exon 3, which translates to a p.Arg166His residue
mutation. E2F1 orthologue conservation analysis was performed using the SNP Analysis function of SNPs3D [15] with the E2F1 mutated protein
sequence shown in light blue (bottom left). The arginine-arginine conservation across diverse species is shown with the histidine mutation
highlighted in red and its arginine partner highlighted in blue. E2F1 paralogue conservation analysis was performed using CLUSTALW [14] at
default settings (bottom right). The E2F1 mutated sequence is shown in light blue and underlined with the histidine mutation shown in red and
its partner arginine shown in blue. Again the arginine-arginine conservation across the E2F family is clearly shown.
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binding ability and negatively affects downstream target
gene expression
In order to conclusively show the effect of the R166H
mutation on DNA binding, chromatin immunopreci-
pitation (ChIP) assays targeting the SIRT1 (sirtuin 1)
and APAF1 (apoptotic peptidase activating factor 1)
promoters using the MSTO-211H cell line over-
expressing E2F1 (wild type and mutant) were per-
formed. The mutant E2F1 (Figure 6a, lane 7) showed
significantly decreased levels of APAF1 (top) and
SIRT1 promoter DNA binding (bottom) when com-
pared with wild-type E2F1 (Figure 6a, lane 6),
although the amount of input DNA for the E2F1
mutant was greater than for the E2F1 wild type (Fig-
ure 6a, lanes 2 and 3, respectively). The ChIP result
indicates that the R166H mutation has a detrimental
effect on E2F1’s DNA binding ability.
To show that the R166H mutant’s reduced DNA bind-
ing affinity affected the expression of E2F1 target genes,
the expression of SIRT1, APAF1 and CCNE1 (cyclin E1)
was examined by real-time PCR in MSTO-211H and
NCI-H28 cell lines that were transfected with the E2F1
mutant or wild type. Interestingly, over-expression of
the E2F1 R166H mutant (E2F1-R166H) did not up-regu-
late expression of SIRT1 and APAF1 as high as over-
expression of wild-type E2F1 in both cell lines (Figure
6b, c). In particular, levels of SIRT1 and APAF1 expres-
sion in MSTO-211H cells observed with E2F1-R166H
were significantly lower than those with the E2F1 wild
type (P = 0.032 for SIRT1 and P = 0.005 for APAF1).
However, the expression of cyclin E1, a well known
C
C
DNA DP2
E2F
C
C
G
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R182
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R166
R167
Figure 4 Visualization of the p.Arg166His mutation in E2F1. Top: the E2F4 crystal structure [PDB:1CF7] showing the location of the p.
Arg166His mutation. The brown double helix is the DNA binding motif with green colored guanine nucleotides representing binding targets of
Arg182 and Arg183 of the DP2 protein and yellow colored guanine nucleotides representing binding targets of Arg166 and Arg165 of the E2F
protein. The blue ribbon represents the DNA binding region of E2F with the Arg166 mutation in red and Arg165 in blue, while the purple
ribbon represents the DNA binding region of DP2 with Arg182 and Arg183 in purple. Bottom: a schematic showing binding of E2F residues to
DNA binding site nucleotides.
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Page 5 of 14target of E2F1 [21], was minimally affected in the over-
expression context, which may be indicative of a com-
pensatory effect by other members of the E2F family.
Cells over-expressing E2F1-R166H show massive protein
accumulation and increased protein stability
To study cellular phenotypes that might be affected by
the R166H mutation, we initially over-expressed the
mutant and wild type in the MSTO-211H and NCI-H28
cell lines. Surprisingly, an obvious difference in E2F1
protein levels between wild type and mutant was
observed in both cell lines as determined by western
blot (Figure 7a). In order to ensure the protein differ-
ences were not due to differences in transfection effi-
ciency, the two cell lines were co-transfected with E2F1
and enhanced green fluorescent protein (EGFP) vectors
simultaneously with protein lysate obtained at 48 hours
after transfection for western blot analysis. Clearly, the
levels of expression of the E2F1 wild type and mutant
were similar when normalized to EGFP levels (Addi-
tional file 4), indicating that the transfection efficiency
of E2F1-R166H is not different from that of the wild
type. This suggests that the large increase in the level of
the mutant E2F1 protein might be caused by other
mechanisms, such as increased protein stability.
To monitor E2F1 protein stability, we over-expressed
the E2F1 wild type and mutant in MSTO-211H cells
before treating the cells with 25 μg/ml cyclohexamide to
block new protein synthesis in half hour intervals. As
s h o w ni nF i g u r e6 b ,t h ep r o t e i nl e v e l so ft h eE 2 F 1
mutant remained almost constant throughout the 3-
hour period of the experiment while those of the wild
type decreased in a time-dependent manner. This result
suggests that the mutant protein is more stable and
E2F1 WT E2F1 MUT
ANOLEA
GROMOS
E2F1 WT E2F1 MUT
Figure 5 Homology modeling of wild-type and mutant E2F1 around the R166 residue. Homology modeling of the E2F1 DNA binding
domain using SWISS-MODEL [18]. Top: ANOLEA (Atomic Non-Local Environment Assessment) [19] and GROMOS (Groningen Molecular
Simulation) [20] were used by SWISS-MODEL to assess the quality of the model structure of the E2F1 wild-type and E2F1 R166H mutant DNA
binding domain. The y-axis represents the energy for each amino acid of the protein, with negative energy values (in green) representing a
favorable energy environment and positive energy values (in red) representing unfavorable energy environments. Bottom: the predicted three-
dimensional structure of residues VQK(R/H)R with the wild-type arginine-arginine residues shown in purple (bottom left), the mutated histidine
residue shown in red and its arginine neighbor shown in blue (bottom right). The side chain of the histidine mutation is clearly predicted to be
oriented approximately 90 degrees counterclockwise compared to the side chains of its wild-type arginine counterpart.
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Page 6 of 14resistant to degradation than the wild type and the
increased stability of E2F1-R166H is the cause of its
accumulation within cells over-expressing it.
Over-expression of E2F1-R166H does not adversely affect
cell proliferation
S i n c et h eR 1 6 6 Hm u t a n ti sd e m o n s t r a t e dt oh a v e
exceptional stability and accumulates greatly in cells
over-expressing it, it would be instructive to observe
what effect, if any, it has on cell proliferation. A prolif-
eration assay was performed on the transiently trans-
fected cell lines. The results showed that high
expression of the E2F1 wild type slightly decreased the
growth rate of cells whereas high expression of the
mutant resulted in a slightly better growth rate (Figure
8a, b). Although E2F1-R166H does not show a signifi-
cant effect on regulating cell proliferation, it is possible
that the mutation is advantageous to cancer cells as it
does not inhibit cell growth when the mutant is highly
expressed in cells.
Discussion
For this study we have performed the first exome
sequencing of a matched pair of WDPMP samples along
with a cell line derived from the tumor. Analysis of the
exomes revealed none of the chromosomal aberrations
or focal gene deletions commonly associated with asbes-
tos-related malignant mesothelioma. We were able to
verify somatic mutations in PPFIBP2, TRAF7 and E2F1.
TRAF7 is an E3 ubiquitin ligase [21] shown to be
involved in MEKK3 (mitogen-activated protein kinase
kinase kinase 3) signaling and apoptosis [22]. The
Y621D mutation in TRAF7 occurs in the WD40 repeat
domain, which has been shown to be involved in
MEKK3-induced activator protein 1 (AP1) activation
[22]. Since AP1 in turn controls a large number of cellu-
lar processes involved in differentiation, proliferation
and apoptosis [23], this mutation in TRAF7’sW D 4 0
repeat domain may de-regulate MEKK3’s control over
AP1 activation, which may contribute to WDPMP
transformation.
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Sirt1                      Apaf1                      CyclinE1 Sirt1                      Apaf1                      CyclinE1
Input            IgG           anti-Myc tag
Ctrl
E2F1 WT
E2F1- R166H
300 bp
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E2F1- R166H
No template ctrl
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WT
R166H
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Figure 6 Mutation of R166 in E2F1 affects its efficiency of binding to promoter targets. (a) ChIP assay on MSTO-211H cells transiently
transfected with E2F1 wild type (WT) or E2F1-R166H (R166H) for 48 hours using anti-Myc antibody. The amplification levels of the APAF1 (top)
and SIRT1 (bottom) promoters were determined by PCR. Anti-IgG antibody was used as negative control. (b, c) Expression levels of E2F1 targets
- SIRT1, APAF1, and CCNE1 - in MSTO-211H and NCI-H28 cells that were transfected with the indicated plasmids. Each bar represents mean ±
standard deviation (n =3 ;* P < 0.05, **P < 0.01). Ctrl, empty vector.
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Page 7 of 14PPFIBP2 is a member of the LAR protein-tyrosine-
phosphatase-interacting protein (liprin) family [24].
While no functional studies on PPFIBP2 have been pub-
lished, it was reported as a potential biomarker for
endometrial carcinomas [25]. However, the Q791H
mutation in PPFIBP2 is predicted by Polyphen to be
benign and the Catalogue of Somatic Mutations in Can-
cer (COSMIC) did not show this particular mutation to
occur in other cancers; thus, this mutation is likely to
be of a passenger variety.
(a)
(b)
MSTO-211H NCI-H28
Time (min)
0     30      60       90        120        180
actin
E2F1
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E2F1-R166H
E2F1-WT
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E2F1-WT
R166H
R166H
E2F1-WT
Ctrl
Figure 7 Accumulation of mutant E2F1 protein in cells due to increased stability of E2F1-R166H. (a) E2F1 protein levels detected by anti-
E2F1 antibody (KH95) 48 hours after transfection. WT, wild type. (b) Degradation assay performed in MSTO-211H cells over-expressing E2F1
treated with 25 μg/ml cycloheximide. Levels of E2F1 protein were monitored every 30 minutes for 3 hours using anti-E2F1 antibody.
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Figure 8 Over expression of the E2F1 R166H mutant in two mesothelial cell lines. (a, b) Proliferation assay after over-expressing the
E2F1wild type (E2F1-WT) or mutant (E2F1-R166H) or empty vector (Ctrl) in MSTO-211H and NCI-H28 cells. Cells were transfected with the
indicated plasmids for 48 hours. Data are means ± standard deviation (n = 3).
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Page 8 of 14Of particular interest is the E2F1 mutation as no
reported somatic mutation has ever been reported for
this protein despite its critical roles in cell cycle control
[26], apoptosis [27] and DNA repair [28]. Using various
bioinformatics tools, this mutation was identified to
mutate an arginine residue into a histidine residue, thus
altering a critical evolutionarily conserved DNA contact
point responsible for DNA binding and motif
recognition.
Since computational modeling is sufficient to pinpoint
the mutation’s structural location but is inconclusive in
showing the mutation’s functional effect on DNA bind-
ing, we performed a ChIP assay that showed the R166H
mutation abrogates E2F1 DNA binding. Analysis of
expression of selected E2F1 target genes in an over-
expression system showed the inability of the E2F1
mutant to adequately up-regulate the expression of
SIRT1 and APAF1 when compared with the E2F1 wild
type. Of interest is the lack of changes in the expression
of the gene encoding cyclin E1, a known target of E2F1
and an important component in starting the S phase of
the cell cycle. A possible explanation for this is the func-
tional redundancy of the E2F family to ensure the cell’s
replication machinery is operational - for example, mice
studies have shown that E2F1-/- mice can be grown to
maturity [29,30].
Our study has also shown that the R166H mutant is
much more stable than its wild-type counterpart,
enabling massive accumulation within the cell. A pre-
vious study showed that over-expression of E2F1 results
in induction of apoptosis [31], which is in line with our
observation of a drop in proliferation when cells were
over-expressing wild-type E2F1; curiously, over-expres-
sion of the mutant E2F1 protein did not lead to any
noticeable effect on cellular proliferation even though
mutant protein levels were many fold higher than those
of the wild type in equivalent transfection conditions.
One explanation for this phenomenon is that inactiva-
tion of E2F1 decreases apoptosis and its abrogated cell
cycle role is compensated for by other members of its
family. E2F1-/- mice can grow to maturity and repro-
duce normally but display a predisposition to develop
various cancers [30], indicating the greater importance
of the tumor suppressive function of E2F1 compared to
its cell cycle gene activation function.
An alternative but not mutually exclusive explanation
is that stable and numerous E2F1-R166H proteins
behave functionally like SV40 large T antigens, serving
as competitive inhibitors by taking up the lion’s share of
the binding capacity of retinoblastoma protein 1 (Rb),
resulting in unbound wild-type E2F1, which drives the
cell cycle. While the R166H mutation cripples E2F1’s
DNA binding ability, its other interaction domains,
including the Rb interaction domain, are still active. The
mutant’s stability and large quantities will favor its pre-
ferential binding to Rb due to its sheer numbers and the
heterozygous nature of them u t a t i o ni nt h eW D P M P
tumor would ensure active copies of wild-type E2F1
were present to drive the cell cycle. This theory is sup-
ported by two studies: Cress et al. [32] created an E2F1-
E132 mutant that is artificially mutated in position 132
within E2F1’s DNA binding domain and that was
demonstrated to have lost its DNA binding capacity,
like our R166H mutant; Halaban et al. [33] demon-
strated that expression of the E2F1-E132 mutant can
induce a partially transformed phenotype by conferring
growth factor-independent cell cycle progression in
mice melanocytes. One possible reason why the prolif-
eration of cells over-expressing the E2F1 mutant was
not greater than that of control cells is that both
mesothelial cell lines used in this study already have a
homozygous deletion of the CDKN2A gene resulting in
p16 null cells. A key part of the G1/S checkpoint of the
cell cycle is p16 deactivation of cyclin-dependent kinase
6, which keeps Rb hypophosphoyylated, thus keeping
E2F1 sequestered [34]. A p16 null cell has already lost
its G1/S checkpoint control; thus, introducing another
mutation that will cause the same checkpoint loss will
not cause noticeable growth differences.
G i v e nt h a tW D P M Pi sar a r es u b - t y p eo fm e s o t h e -
lioma, it is of interest to extrapolate E2F1’sr o l et ot h e
more prevalent MPM. Given that CDKN2A homozygous
deletion is prevalent in MPM, with up to 72% of tumors
affected [35], the G1/S checkpoint is already broken in
CDKN2A deleted tumors; thus, in terms of proliferation
it is unlikely that an additional E2F1 R166H mutation
will be useful as the mutation will be redundant in this
context. On the other hand, E2F1 also plays an impor-
tant role in the activation of apoptosis pathways [27],
and the R166H mutation, with its abrogated DNA bind-
ing, may contribute to the survival of the cancer cell
harboring this mutation. It would be worth checking the
remaining 28% of MPMs without CDKN2A deletion for
possible mutations in E2F1 and other related genes. It is
interesting to note that BAP1 (BRCA1 associated pro-
tein-1), a nuclear deubiquitinase affecting E2F and Poly-
comb target genes, was recently shown to be inactivated
by somatic mutations in 23% of MPMs [36], suggesting
that the genes within the E2F pathways might play an
important role in mesothelioma in general.
Conclusions
We have performed the first exome sequencing of a
WDPMP tumor and a matched control sample and a
tumor-derived cell line and discovered the first somatic
mutation of E2F1, R166H. This mutation is found to be
the critical DNA contact point in the protein’sD N A
binding domain responsible for gene activation and
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mutation abrogates DNA binding and renders the
mutated protein unable to adequately up-regulate its
target genes. Large accumulation of the mutant protein
is observed in over-expression studies and this is due to
a great increase in protein stability as shown by a cyclo-
hexamide chase assay. Overall, two compatible theories
can explain the observed results: first, E2F1-R166H
decreases apoptosis and its abrogated cell cycle role is
compensated for by other members of its family; and
second, heterozygous E2F1-R166H behaves like SV-40
large T antigen, interfering with the tumor suppressive
role of Rb and allowing its wild-type counterpart to
drive cell division.
Materials and methods
Patient materials
Tumor and blood samples were collected from a 41-year-
old Chinese female who was diagnosed with WDPMP
after a laparoscopic biopsy of the omental nodules that
were found during a computerized tomography scan.
The patient underwent cytoreductive surgery and
hyperthermic infusion of intraperitoneal chemotherapy.
She completed 5 days of early post-operative intraperito-
neal chemotherapy whilst hospitalized, and recovered
uneventfully without any complications. She was dis-
charged on post-operative day 15 and remains disease-
free at 8 months after her surgery. Informed consent for
tissue collection was obtained from the patient by Sin-
gHealth Tissue Repository (approved reference number
10-MES-197) and this study was approved by the Sin-
gHealth Centralised Institutional Review Board (CIRB
reference number 2010-282-B).
Cell line establishment
Fresh tumor sections were first minced into a paste
using surgical scissors in a sterile petri dish and the
minced section was transferred to a 50-ml falcon conical
tube along with 10 ml of 0.1% collagenase (C5138;
Sigma, St. Louis, MO, USA) and incubated for 1 hour at
37°C. RPMI1640 (40 ml) was then added to the tube
and spun for 5 minutes at 500 g after which the super-
natant was removed and the process repeated until the
pellet had a white color. The pellet was re-suspended
with 14 ml of RPMI1640 containing 10% fetal bovine
serum and antibiotics and seeded onto a T-75 flask. The
flask was incubated for 24 hours at 37°C in a 5% CO2
environment before being checked under the micro-
scope for cell attachment to the flask surface and the
cells were passaged every 3 days.
Extraction of DNA from patient samples and cell lines
For sample DNA extraction, approximately 15 to 20 mg
of frozen tissue was measured out and the sample
pulverized into a fine powder using a mortar and pestle;
the powdered sample was then added to a 15-ml falcon
tube containing 2 ml Master mix containing 4 μlo f
Rnase A, 100 μl of QIAGEN (Valencia, CA, USA) pro-
tease and 2 μl of Buffer G2 and mixed thoroughly. The
mixture was incubated in a 50°C incubator for 24 hours
then spun at maximum speed for 25 minutes before the
supernatant was extracted.
DNA was then extracted from the supernatant using
QIAGEN’s Blood and Cell Culture Mini kit according to
the manufacturer’s instructions. In brief, the supernatant
was loaded into the kit-supplied column (Genomic-Tip
20/G) and the flow-through was discarded. The column
was then washed and DNA eluted into a falcon tube
and isopropanol added to precipitate the DNA. The
tube was then spun at maximum speed for 15 minutes
before washing twice with 70% ethanol. The ethanol was
discarded and the remaining DNA pellet re-suspended
in TE buffer.
Exome capture and paired-end sequencing
Sample exomes were captured using Agilent SureSelect
Human All Exon Kit v1.01 designed to encompass 37.8
Mb of the human exon coding region. DNA (3 μg) from
the WDPMP tumor, matched blood sample and the
tumor-derived cell line were sheared, end-repaired and
ligated with paired-end adaptors before hybridizing with
biotinylated RNA library baits for 24 hours at 65°C. The
DNA-bait RNA fragments were captured using strepta-
vidin-coated magnetic beads and the captured fragments
were RNA digested, with the remaining DNA fragments
PCR amplified to generate the exon captured sequen-
cing library.
A 15 picomolar concentration of the exome library
was used in cluster generation in accordance with Illu-
mina’s v3 paired-end cluster-generation protocol. The
cluster-generated flow cell was then loaded into the
GAIIx sequencer to generate the 76 bp of the first read.
After first read completion, the paired end module of
GAIIx was used to regenerate the clusters within the
flow cell for another 76 bp sequencing of the second
read. All raw sequencing data generated are available at
the NCBI Sequence Read Archive [37] [SRA:
SRP007386].
Sequence mapping and filtering criteria
Illumina paired-end reads were first converted from Illu-
mina quality scores to Sanger quality scores using the
converter module of MAQ before paired-end read align-
ment to the NCBI hg18 build 36.1 reference genome
using the short read aligner BWA (Burrows-Wheeler
Aligner) [9] with default options. The aligned output
from BWA was processed by SAMtools [10] in the fol-
lowing manner. The BWA output was first converted
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sequences were sorted according to chromosomal coor-
dinates. The sorted sequences were then subjected to
SAMtools’ PCR duplicate removal module to discard
sequence pairs with identical outer chromosomal coor-
dinates. Because each sample was sequenced in dupli-
cate, the resulting BAM files representing the duplicate
lanes were merged into a single BAM file before the
quality filtering step. Quality filtering involved selecting
sequences that were uniquely aligned with the reference
genome, had less than or equal to four mismatches to
the reference genome and had a mapping quality score
o fa tl e a s to n e .T h eo u t p u tr e s u l to ft h i sf i l t e rf o r m e d
the core sequence file for further downstream analysis.
Generation of exome Hilbert plots
Using the core sequence file described above, we first
discarded all intronic bases in the following manner.
First, conversion was performed on Agilent’s SureSelect
exon coordinates file from BED format into space-
delimited format specifying the chromosomal location of
every exon base. SAMtools’ pileup command, using the
space-delimited exon coordinate file as a parameter, was
used to exclusively output only bases belonging to the
exome. Since the pileup command was coded to output
only bases with non-zero depth to conserve storage, a
quick R script was used to insert in the exome bases
that are of zero depth into the initial exome pileup out-
put. This final pileup contains every nucleotide of the
exome and its associate sequencing depth sorted by
chromosomal coordinates. For the visualization of the
entire exome, we used the statistical program R, and in
particular HilbertVis, a compact graphical representation
of linear data packages [11]. Instead of linearly plotting
the sequencing depth versus the exome DNA string, a
Hilbert plot computationally wraps the DNA string in a
fractal manner onto a two-dimensional grid of pre-
determined size and represents the coverage depth via a
heat map similar to gene expression data. Red and blue
color heat mapping is used to demarcate the borders of
each chromosome.
Single nucleotide variant discovery
Additional file 5 shows the SNV discovery pipeline.
Aligned reads were processed using Genome Analyzer
Toolkit [13]. Reads containing microindels were first
locally re-aligned to obtain more accurate quality scores
and alignments then quality filtered before consensus
calling was performed to obtain the raw SNVs. These
raw SNVs were subjected to further quality filtering
before being compared against dbSNP130 and 1000
Genomes databases where common SNPs present in the
exome were discarded; from this pool of remaining
SNVs, only non-synonymous variations occurring in
exons or splice sites were retained. This pipeline was
performed for tumor, normal sample and cell line
exomes and only SNVs that had a quality/depth score >
3 and were present in both the tumor and cell line and
not in the normal sample were retained; SNVs in this
final pool were considered to be candidate somatic
mutations.
Sanger sequencing validation
Primers for sequencing validation were designed using
Primer3 [38]. Purified PCR products were sequenced in
forward and reverse directions using the ABI PRISM
BigDye Terminator Cycle Sequencing Ready Reaction
kit (version 3) and an ABI PRISM 3730 Genetic Analy-
zer (Applied Biosystems, Foster City, CA, USA). Chro-
m a t o g r a m sw e r ea n a l y z e db yS e q S c a p eV 2 . 5a n db y
manual review. The validation PCR primers were (where
F and R stand for forward and reverse, respectively):
E2F1_F, 5’ GCAGCCACAGTGGGTATTACT 3’;
E2F1_R, 5’ GGGGAGAAGTCACGCTATGA 3’;
TRAF7_F, 5’ GCCTTGCTCAGTGTCTTTGA 3’;
TRAF7_R, 5’ CATGTTGTCCATACTCCAGACC 3’;
PPFIBP2_F, 5’ CCCTCGAGCCATTTGTATTT 3’;
PPFIBP2_R, 5’ CCACAGCAGAAGCTGAAAGA 3’.
Protein visualization and homology modeling
Protein modeling of the mutated and wild-type DNA
binding domain of E2F1 was done using the automated
mode of SWISS-MODEL [18], a web-based fully auto-
mated protein structure homology-modeling server. The
basic input requirement from the user is the protein
sequence of interest or its UniProt AC code (if avail-
able). Swiss-PDBviewer [16] provides an interface allow-
ing users to visualize and manipulate multiple proteins
simultaneously. Structures generated by SWISS-MODEL
or experimentally determined structures archived at the
RCSB Protein Data Bank [39] can be downloaded in a
compact.pdb format that serves as the input source for
this viewer.
Mesothelioma cell lines and mutant plasmid generation
The mesothelioma cell lines MSTO-211H and NCI-H28
(ATCC catalogue number CRL2081 and CRL5820,
respectively) were cultured in RPMI-1640 supplemented
with 10% fetal bovine serum (v/v). Total RNA extracted
from the heterozygous E2F1 mutated mesothelioma
sample was used for cDNA synthesis using an iScrip
cDNA Synthesis Kit (Bio-Rad, Hercules, CA, USA). Full-
length wild-type and mutant E2F1 were amplified using
iProof DNA polymerase (Bio-Rad) and E2F1 primers.
The primer sequences were: E2F1-ORF-F, 5’-AGT-
TAAGCTTGACCATGGCCTTGGCCGGGG-3’; E2F1-
ORF-R, 5’-AGAATTCCAGAAATCCAGGGGGGT-
GAGGT-3’. The PCR products were subsequently
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CA, USA) using HindIII and EcoRI. Plasmids expressing
wild-type E2F1 (pcDNA6-E2F1) or mutant E2F1
(pcDNA6-E2F1/R166H) were validated by dideoxy ter-
minator sequencing. pcDNA3-EGFP was constructed as
described previously [40].
Chromatin immunoprecipitation
ChIP was carried out in MSTO-211H cells transiently
transfected with wild-type E2F1 and E2F1-R166H for 48
hours. Transiently transfected cells were cross-linked
with 1% formaldehyde. Chromatin solution pre-cleared
with protein G sepharose 4 fast flow (GE Healthcare
Life Sciences, Piscataway, NJ, USA) was used for immu-
noprecipitation with anti-Myc tag antibody (ab9132;
Abcam, Boston, MA, USA) targeting Myc tag at the car-
boxyl terminus of E2F1. Co-precipitated chromatin was
eluted from complexes and purified by QIAquick PCR
Purification Kit (QIAGEN, Valencia, CA, USA). The
presence of SIRT1 and APAF1 promoter was analyzed
by semi-quantitative PCR using 2 μlf r o m3 5μlo fD N A
extraction and GoTaq DNA Polymerase (Promega,
Madison, WI, USA). Primer sequences used were: Apaf-
1p r o - F ,5 ’-GGAGACCCTAGGACGACAAG-3’;A p a f - 1
pro-R, 5’-CAGTGAAGCAACGAGGATGC-3’.P r i m e r s
specific for the SIRT1 promoter have been described
previously [41]. PCR products were resolved on 2%
agarose gel containing ethidium bromide.
Quantitative real-time PCR
Total RNA was extracted using TriPure (Roche, India-
napolis, IN, USA). Total RNA (1 μg) was subjected to
cDNA synthesis using an iScrip cDNA Synthesis Kit
(Bio-Rad). Expression of target genes was examined
using specific primers in combination with SsoFast
EvaGreen Supermix usingaC F X 9 6R e a l - T i m eP C R
Detection System (Bio-Rad). Primers used for detecting
E2F1 targets were: SIRT1-F, 5’-TGGCAAAGGAGCA-
GATTAGTAGG-3’;S I R T 1 - R ,5 ’-TCATCCTC-
CATGGGTTCTTCT-3’;C y c l i nE 1 - F ,5 ’-
GGTTAATGGAGGTGTGTGAAGTC-3’; Cyclin E1-R,
5’-CCATCTGTCACATACGCAAACT-3’;A P A F 1 - F ,5 ’-
TGACATTTCTCACGATGCTACC-3’;A P A F 1 - R ,5 ’-
ATTGTCATCTCCCGTTGCCA-3’;G A P D H - F ,5 ’-
GTGGACCTGACCTGCCGTCT-3’;G A P D H - R ,5 ’-
GGAGGAGTGGGTGTCGCTGT-3’.P r i m e r su s e df o r
determining transfection efficiency were: E2F1-F, 5’-
GCTGAAGGTGCAGAAGCGGC-3’;E 2 F 1 - R ,5 ’-
TCCTGCAGCTGTCGGAGGTC-3’;E G F P - F ,5 ’-
CTACGGCGTGCAGTGCTTCA-3’;E G F P - R ,5 ’-
CGCCCTCGAACTTCACCTCG-3’.
Relative expression levels of transcripts were normal-
ized with glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) expression level.
E2F1 over-expression
E2F1 plasmids were transiently transfected into
MSTO-211H and NCI-H28 cells through the use of
Effectene (QIAGEN) according to the manufacturer’s
instructions. Briefly, cells were plated at a density of
60% in a six-well plate. The next day, cells were trans-
fected with 0.4 μg pcDNA6-E2F1, pcDNA6-E2F1/
R166H or empty vector using Effectene. After a 48-
hour transfection period, the cells were harvested for
downstream assays. To determine transfection effi-
ciency, 0.1 μg of pcDNA3-EGFP was co-transfected
with 0.3 μgo fE2F1 plasmids. Cells were collected for
RNA and protein extraction after a 48-hour transfec-
tion. Expression of EGFP and E2F1 transcripts was
assessed by real-time PCR.
Western blot analysis
Cells were lysed in phosphate-buffered saline contain-
ing 1% triton-X100 in the presence of protease inhibi-
tor (Roche, Indianapolis, IN, USA). Total protein
extracts (20 μg) were separated using 8% SDS-PAGE,
transferred to nitrocellulose membranes and probed
with antibody specific for E2F1 (KH95; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and b-actin
(AC-15; Sigma).
Degradation assay
MSTO-211H cells were transfected with 4 μgo fw i l d -
type E2F1 or E2F1-R166H in a 99-mm dish. After 24
hours, cells were harvesteda n ds p l i ti n t oas i x - w e l l
plate. After 20 hours, cells were treated with RPMI
containing 25 μg/ml cycloheximide (Sigma). Cells were
collected at 30 minute time points and lysed in lysis
buffer containing 1% triton-X100 and protease inhibi-
tor. The E2F1 level was then determined by western
blot.
Proliferation assay
Transfected cells were seeded into a 96-well plate at a
density of 2 × 10
3 cells after a 48-hour transfection per-
iod. Proliferation rates for cells over-expressing wild-
type E2F1 and E2F1-R166H were assessed using the col-
orimetric 3-(4,5-dimethylthiazol-2yl)-5-(3-carboxy-
methoxyphenyl)-(4-sulfophenyl)-2H-tetrazoluim assay
according to the manufacturer’sp r o t o c o l( M T S ;P r o -
mega). The assay was performed in triplicate and
repeated three times independently.
Statistical analyses
Statistical analyses were performed with PASW Statistics
18.0 (IBM, Endicott, NY, USA). Differences between
individual groups were analyzed using ANOVA followed
by post hoc analysis. P-values of < 0.05 are considered
statistically significant.
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Additional file 1: Sequencing coverage at CDKN2A, RASSF1A and
NF2. Each graph shows the exons (brown box) and introns (brown line)
as defined by ENSEMBL, the chromosome and chromosomal coordinates
of the gene, the actual capture region as defined by Agilent SureSelect
Human All Exon Kit v1.01 (gray box with green outlines or green lines if
the capture region is very small relative to the distance between exons),
and three plots showing sequencing depth versus chromosomal
coordinates for the tumor, the normal sample and the cell line.
Additional file 2: Full candidate somatic mutation set with
validation using Sanger sequencing. Full data set containing
computationally predicted somatic single nucleotide alterations with a
quality by depth of at least three. The data set was also validated using
Sanger sequencing.
Additional file 3: Sanger sequencing validation of E2F1, PPFIBP2
and TRAF7 for tumor, normal and cell line samples. Heterozygous
mutation (red arrow) on E2F1, PPFIBP2, and TRAF7 presented in the tumor
and cell line compared to the normal sample.
Additional file 4: Relative expression of E2F1 wild type or E2F1
mutant after co-transfection with EGFP in MSTO-211H and NCI-H28
cells. E2F1 levels were normalized to EGFP levels in each condition.
Similar levels of transcripts of the R166H mutant and wild type E2F1 were
observed.
Additional file 5: Schematic for detection of somatic single
nucleotide variants in high-throughput sequencing data. Flowchart
describing computational detection of somatic single nucleotide variants
in exome sequencing data.
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